Benjamin Scherlag to Bridged Bicyclo Compounds, Heterocyclic
This is a "connection" page, showing publications Benjamin Scherlag has written about Bridged Bicyclo Compounds, Heterocyclic.
Connection Strength
0.521
-
Electrophysiologic actions of d,l-sotalol and GLG-V-13 in ischemically injured canine epicardium. J Cardiovasc Pharmacol. 2007 Sep; 50(3):304-13.
Score: 0.072
-
The acute and subchronic toxicity of BRB-I-28, a novel class Ib antiarrhythmic agent, in CD-1 mice. Food Chem Toxicol. 2000 Sep; 38(9):817-23.
Score: 0.044
-
Effect of GLG-V-13, a class III antiarrhythmic agent, on potassium currents in rabbit ventricular myocytes. Life Sci. 2000 Mar; 66(17):PL 253-8.
Score: 0.043
-
Preliminary acute and subchronic toxicity studies of GLG-V-13, a novel class III antiarrhythmic agent, in mice. Arzneimittelforschung. 2000 Jan; 50(1):31-8.
Score: 0.042
-
Electrophysiological and inotropic characterization of a novel class III antiarrhythmic agent, GLG-V-13, in the mammalian heart. J Cardiovasc Pharmacol. 1996 Aug; 28(2):182-91.
Score: 0.033
-
Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nona ne dihydroperchlorate. J Med Chem. 1996 Jun 21; 39(13):2559-70.
Score: 0.033
-
Pharmacokinetics and plasma protein binding of the new potent class III antiarrhythmic agent 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3, 7-diazabicyclo[3.3.1]nonane dihydroperchlorate. Arzneimittelforschung. 1995 Jun; 45(6):670-5.
Score: 0.031
-
Electrophysiological characterization of a novel class III antiarrhythmic agent, GLG-V-13 in the mammalian heart. Acta Physiol Hung. 1995; 83(1):13-30.
Score: 0.030
-
Effects of novel antiarrhythmic agents, BRB-I-28 and its derivatives, on the heart mitochondrial respiratory chain and sarcoplasmic reticulum Ca(2+)-ATPase. Res Commun Mol Pathol Pharmacol. 1994 Aug; 85(2):193-208.
Score: 0.029
-
Electrophysiologic actions of BRB-I-28 in ischemically injured canine myocardium. J Cardiovasc Pharmacol. 1993 Apr; 21(4):637-46.
Score: 0.026
-
The comparative antiarrhythmic and proarrhythmic activity of a 3,7-diheterobicyclo[3.3.1]nonane, BRB-I-28, and lidocaine in the 1-4-day-old infarcted dog heart. Acta Physiol Hung. 1993; 81(3):289-99.
Score: 0.026
-
High-performance liquid chromatographic determination of BRB-I-28, a novel antiarrhythmic agent, in dog plasma and urine. J Chromatogr. 1992 Dec 02; 583(2):274-9.
Score: 0.026
-
Effects of BRB-I-28, a novel antiarrhythmic agent, and its derivatives on cardiac Na+,K(+)-ATPase, Mg(2+)-ATPase activities and contractile force. Res Commun Chem Pathol Pharmacol. 1992 Oct; 78(1):3-16.
Score: 0.025
-
The cardiovascular and antiarrhythmic properties of a series of novel sparteine analogs. Proc West Pharmacol Soc. 1992; 35:87-91.
Score: 0.024
-
Electrophysiological actions of BRB-I-28 in canine myocardial tissues. J Pharmacol Exp Ther. 1991 Nov; 259(2):558-65.
Score: 0.024
-
Synthesis, conformational analysis, and antiarrhythmic properties of 7-benzyl-3-thia-7-azabicyclo[3.3.1]nonan-9-one, 7-benzyl-3-thia-7-azabicyclo[3.3.1]nonane hydroperchlorate, and 7-benzyl-9-phenyl-3-thia-7-azabicyclo[3.3.1]nonan-9-ol hydroperchlorate and derivatives: single-crystal X-ray diffraction analysis and evidence for chair-chair and chair-boat conformers in the solid state. J Med Chem. 1984 Jun; 27(6):758-67.
Score: 0.014